4-1BB-mediated immunotherapy of rheumatoid arthritis
- 26 September 2004
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 10 (10), 1088-1094
- https://doi.org/10.1038/nm1107
Abstract
Collagen type II-induced arthritis is a CD4(+) T-cell-dependent chronic inflammation in susceptible DBA/1 mice and represents an animal model of human rheumatoid arthritis. We found that development of this condition, and even established disease, are inhibited by an agonistic anti-4-1BB monoclonal antibody. Anti-4-1BB suppressed serum antibodies to collagen type II and CD4(+) T-cell recall responses to collagen type II. Crosslinking of 4-1BB evoked an antigen-specific, active suppression mechanism that differed from the results of blocking the interaction between 4-1BB and its ligand, 4-1BBL. Anti-4-1BB monoclonal antibodies induced massive, antigen-dependent clonal expansion of CD11c(+)CD8(+) T cells and accumulation of indoleamine 2,3-dioxygenase in CD11b(+) monocytes and CD11c(+) dendritic cells. Both anti-interferon-gamma and 1-methyltryptophan, a pharmacological inhibitor of indoleamine 2,3-dioxygenase, reversed the anti-4-1BB effect. We conclude that the suppression of collagen-induced arthritis was caused by an expansion of new CD11c(+)CD8(+) T cells, and that interferon-gamma produced by these cells suppresses antigen-specific CD4(+) T cells through an indoleamine 2,3-dioxygenase-dependent mechanism.Keywords
This publication has 27 references indexed in Scilit:
- CTLA-4–Ig regulates tryptophan catabolism in vivoNature Immunology, 2002
- Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic CellsThe Journal of Experimental Medicine, 2002
- In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responsesNature Immunology, 2002
- Gene therapy for cancer using single-chain Fv fragments specific for 4-1BBNature Medicine, 2002
- Anti–4-1bb Monoclonal Antibodies Abrogate T Cell–Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell AnergyThe Journal of Experimental Medicine, 1999
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumorsNature Medicine, 1997
- The pathophysiology and treatment of rheumatoid arthritisArthritis & Rheumatism, 1997
- The effect of treatment with interferon-gamma on type II collagen-induced arthritisClinical and Experimental Immunology, 1990
- Pathogenesis of the joint disease of rheumatoid arthritisAmerican Journal Of Medicine, 1983